MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Biocept Retained Earnings 2011-2026 | BIOC
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -298 M | -266 M | - | -246 M | -220 M | -195 M | -174 M | -155 M | -138 M | -122 M | -113 M | -101 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -101 M | -298 M | -185 M |
Quarterly Retained Earnings Biocept
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -309 M | -306 M | -298 M | -280 M | -274 M | -269 M | -266 M | -263 M | -263 M | -261 M | -264 M | -264 M | -264 M | -264 M | -246 M | -246 M | -246 M | -246 M | -220 M | -220 M | -220 M | -220 M | -195 M | -195 M | -195 M | -195 M | -174 M | -174 M | -174 M | -174 M | -155 M | -155 M | -155 M | -155 M | -138 M | -138 M | -138 M | -138 M | -122 M | -122 M | -122 M | -122 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -122 M | -309 M | -211 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 114.87 | -0.65 % | $ 34.9 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.63 | -1.21 % | $ 2.17 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 24.7 | -1.12 % | $ 686 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 21.91 | 0.27 % | $ 1.17 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 15.3 | -1.92 % | $ 463 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 166.79 | -2.59 % | $ 8.27 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 83.09 | -6.11 % | $ 10.4 B | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 126.92 | -1.24 % | $ 20.2 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 83.55 | -0.67 % | $ 5.64 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
-460 M | $ 409.65 | -2.78 % | $ 11.8 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 102.49 | -0.7 % | $ 8.45 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 259.57 | -1.47 % | $ 21.6 B | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 9.02 | 4.76 % | $ 1.16 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 120.07 | -4.46 % | $ 5.61 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.34 | -1.16 % | $ 2.03 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 16.84 | -1.58 % | $ 377 M | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.84 | 0.21 % | $ 448 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 200.17 | -2.06 % | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 195.05 | -0.8 % | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
6.05 B | - | -0.91 % | $ 14.7 B | USA |
 |
Precipio
PRPO
|
-103 M | $ 31.75 | 3.42 % | $ 51 M | USA |
 |
Personalis
PSNL
|
-550 M | $ 5.5 | -7.72 % | $ 326 M | USA |
 |
Senseonics Holdings
SENS
|
-1.02 B | $ 7.18 | -1.24 % | $ 300 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.65 | -12.64 % | $ 179 M | China |